

저자로서 편집자 및 심사자와 소통하기

의편협 교육연수위원회
최인홍


1

논문은 연구자간 소통하는 방법이다

저자는 출판 전에 편집자 및 심사자와
멋지게 소통하여야 한다


2

무수정 *accept*?



3

논문 심사 과정



4

1. Cover letter 작성

2. 심사평에 대한 대처

5

Cover letter 작성

해야 할 것

- 편집장과 개인적으로 소통하는 기회를 살린다
- 해당 잡지 적합성, 창의성을 강조한다
- 다른 잡지에서 심사하고 있지 않음을 밝힌다
- *Conflict of interest* 여부를 밝힌다

하지 말아야 할 것

- 형식적으로 쓴다
- 이전 편지를 다시 사용한다

6

March 7, 2012

Dr. D. F. Williams
Editor-in-Chief
Biomaterials

Dear Dr. D. F. Williams,

I submit the manuscript for publication. We believe that our study will be of wide popular interest to the readers of the *Biomaterials* because our study is based on multidisciplinary collaboration between nanomaterials and immunology.

Using human blood monocytes that were stimulated with small sized silver nanoparticles, we observed inflammasome formation and release of IL-1 β , a critical pro-inflammatory cytokine initiating innate immunity. More importantly, we demonstrated that -----.

This manuscript has never been published and is not currently under evaluation in any other peer-reviewed publication. All authors have read this manuscript and have approved for submission. There are no conflicts of interest.

Thank you for your kind consideration.

Forever yours,

In-Hong Choi, M.D., Ph.D.

Department of Microbiology
Yonsei University College of Medicine
Seodaemun-gu, Yonsei-ro 50
Seoul, Korea (120-752)
Tel: +82-2-2228-1821, Fax: +82-2-392-7088
E-mail: inhong@yuhs.ac

7

March 7, 2012

Dr. D. Williams
Editor-in-Chief
Biomaterials

Dear Dr. D. F. Williams,

We

entitled "-----"

in the *Biomaterials* as an original article



I submit the manuscript for publication. We believe ^① that our study will be of wide popular interest to the readers of the *Biomaterials* because our study is based on multidisciplinary collaboration between nanomaterials and immunology.

Using human blood monocytes that were stimulated with small sized silver nanoparticles, we observed inflammasome formation and release of IL-1 β , a critical pro-inflammatory cytokine initiating innate immunity. More importantly, we demonstrated that -----.

8

- ② This manuscript has never been published and is not currently under evaluation in any other peer-reviewed publication. ③ All authors have read this manuscript and have approved for submission. ④ There are no conflicts of interest.

Thank you for your kind consideration.

Sincerely yours,

Forever yours,

In-Hong Choi, M.D., Ph.D.

Department of Microbiology
Yonsei University College of Medicine
Seodaemun-gu, Yonsei-ro 50
Seoul, Korea (120-752)
Tel: +82-2-2228-1821, Fax: +82-2-392-7088
E-mail: inhong@yuhs.ac



9

March 7, 2012

Dr. D. F. Williams
Editor-in-Chief
Biomaterials

실어주고 싶도록 중요한 결과 기술
(*abstract* 복사하지 말고)

Dear Dr. D. F. Williams:

We submit the manuscript entitled "Inflammasome formation and IL-1 β release by human blood monocytes in response to silver nanoparticles" to be considered for publication in the *Biomaterials* as an original article. We believe that our study will be of wide popular interest to the readers of the *Biomaterials* because our study is based on multidisciplinary collaboration between nanomaterials and immunology.

Using human blood monocytes that were stimulated with small sized silver nanoparticles, we observed inflammasome formation and release of IL-1 β , a critical pro-inflammatory cytokine initiating innate immunity. More importantly, we demonstrated that -----.

This manuscript has never been published and is not currently under evaluation in any other peer-reviewed publication. All authors have read this manuscript and have approved for submission. There are no conflicts of interest.

Thank you for your kind consideration.

Sincerely yours,

In-Hong Choi, M.D., Ph.D.

Department of Microbiology
Yonsei University College of Medicine
Seodaemun-gu, Yonsei-ro 50
Seoul, Korea (120-752)
Tel: +82-2-2228-1821, Fax: +82-2-392-7088
E-mail: inhong@yuhs.ac

저자추천 심사자 제시

10

1. *Cover letter* 작성

2. 심사평에 대한 대처

11

*Peer reviewer*는 어떻게 정하는가?

- 잡지 고유의 심사자 *DB*
- 심사자 또는 편집위원 추천 심사자
- 투고 논문에서 인용한 논문의 저자
- *PubMed* 검색
- 저자 추천 심사자 또는 심사 배제 연구자

12

Editor decision letter

- *Accept*
- *Rejection*
- *Revision: minor, major*



빨리 수정하여 보낼 것

13

Editor decision letter

Example 1. Rejection, do not resubmit

Your paper has been examined by 2 expert reviewers.

Unfortunately, we must decline this manuscript for publication. The reasons for this decision are indicated in the reviewers' comments.

14

Editor decision letter

Example 2. Declined for now, future acceptance possible

Your paper has been examined by 2 expert reviewers. For the reasons explained in the comments, we cannot accept this manuscript for publication in *Yonsei Medical Journal*. We would consider a revised version that takes these criticisms into account but cannot offer assurance that submission of a revised manuscript will lead to acceptance.

15

Editor decision letter

Example 3. Declined for now, future acceptance very likely

Your paper has been examined by 2 expert reviewers. As you will see in their comments, each reviewer finds merit in the work but makes constructive suggestions. Please consider the suggestions carefully, as the changes will produce an article that better serves you and our readers.

16

Major revision 요구에 대한 대응



17

Revision 요구에 대한 대응

재투고 할 것인지 (기한 내)

또는 다른 잡지에 투고할 것인지 결정한다

18

Revision 요구에 대한 대응

- 완벽하게 대답한다
- 예의 바르게 대답한다
- 근거를 가지고 대답한다

19

Critique에 대한 대응

하지 말아야 할 것

- 절망하고 편집자를 비난한다
- 심사 의견 내 *bias*를 찾는다

해야 할 것

- 심사자는 무보수로 일함을 알고 감사히 여긴다
- 평가에 오해가 있더라도 다른 독자가 동일한 오해를 하지 않도록 명확히 한다

20

Critique에 대한 대응

하지 말아야 할 것

- 조급하게 대처한다
- 익명의 심사자가 누구인지 알아본다

해야 할 것

- 필요한 실험을 추가한다
- 공저자와 상의한다

21

Critique에 대한 회신하기 작성 전에

- 심사평을 꼼꼼히 읽는다
- 지적 *point*를 *list*로 만든다
- 추가 실험이 필요한지, *discussion*에서 설명만으로 해결되는지, 참고문헌을 추가해야 하는지 결정한다
- *Control* 추가에 대한 언급이 있는지 확인한다

22

*Critique*에 대한 구체적 회신 작성 전에

- 동료와 공저자에게 심사평을 보여주고 의견을 받는다
- 영문 교정 도움을 받는다

심사평의 내용을 그대로 믿지 말아라
*Confidential comment*가 있다

23

*Critique*에 대한 구체적 회신 작성하기

- 비평에 하나 하나 답한다
- *Manuscript*의 어디에 수정하였는지 표시한다
- 이미 발표된 결과와 상반된 연구라면 막강한 *data*가 필요하다
- *Cover letter*에 수정 부분 요약을 기술한다

세포주보다 일차배양세포, 그 보다는 동물실험이 낫다

24

Critique에 대한 구체적 회신 작성하기

- 전문적이고 존경하는 어투로 작성한다

“심사자가 다 읽은 것 같지 않다. *Page 2*에 언급되어 있다”

“비평이 이해된다. 보충실험 결과를 *result section (page 13)*에 추가하여 결론을 더욱 확실하게 하였다”

“비평이 이해된다. 그러나 추가 실험이 굳이 필요하지는 않은 것으로 판단되어 *page 2*의 기존 결과와 더불어 다른 연구자의 연구를 참고문헌으로 추가하였다”

심사자도 감정이 있으며 전문성 언급은 예민하다

25

Critique에 대한 구체적 회신 작성하기

- 작성한 회신을 다른 연구자에게 보여준다
(내용 뿐 아니라 문체/감정 표현도 검토)

심사자가 1 시간 이상 논문을 검토하였음을 기억하고 *accept* 시키기 위하여 많은 지적을 하였다고 생각하라

26

*Critique*에 대한 구체적 회신 작성하기

- 논문 길이 축소를 요청 받으면
Discussion 및 *Introduction*에서 줄이고
연구 방법은 줄이지 않는다

27

Peer review system

- 심사자도 사람이므로 완벽하지 않다
- 모든 연구자는 심사자가 되기도 하고
저자가 되기도 한다

28

재접수 *cover letter*

Dear Dr. D. F. Williams:

Thank you for giving us an opportunity to revise our manuscript.

Here, in our study we emphasize -----. Our results will give more relevant understanding -----.

The answers to Reviewers' Comments are follows. Some experiments were performed to fulfill the comments and appended as supplementary data. The changes of revised manuscript have been listed as a Table at the end of this letter.

We thank the referees for their detail and specific comments and hope our revised manuscript to be much improved.

29

내용 수정 후 회신

“We revised Introduction section (page 6, paragraph 2) to include additional literature on _____.”

“As suggested, we changed Figure 2 as image style and combined Table 3 and 4 (page 10).”

“We have also rewritten several sentences in the discussion to tone down our enthusiasm and avoid overstatement. (page 15, lines 20-40)”

30

수정 불가능한 경우 회신

“Unfortunately, we did not perform the experiment using primary cells, so we were unable to assess its effect on primary cells. We acknowledge this as a limitation (page 30, lines 1-5).”

“Our decision to use the confocal microscopy rather than a dark field microscopy was informed by several factors. We have added this rationale to Method section (page 5, lines 15-19).”

31

비평을 반박하는 회신

“We agree with the referee that ____, but. . .”

“The referee is right to point out ____, yet. . .”

“We acknowledge that our manuscript might have been ____, but. . .”

“We, too, were disappointed by the low response rate. We agree that this is an important area that requires further research.”

“With all due respect to the reviewer, we believe that this point is not correct.”

비평을 반박하는 회신

“Your Introduction lacks substance because it does not mention the important work of Choi (2007).”



“Despite its importance in other ways, Choi’s work is not concerned with the justification of the hypothesis I tested in this paper. It would be distracting to the logic if I included it.”

33

심사자 의견이 어느 정도 고려되는가?

<i>Peer reviewer</i> 판정	%	최종 <i>accept</i>
<i>Complete agreement not to reject</i>	48	80
<i>Any level of disagreement</i>	45	29
<i>Complete agreement to reject</i>	7	11
<i>Total</i>	100	

마지막에

Major Changes in the Revised Manuscript

No.	Contents	Changes
1	Staining results for JC-1 have been changed to histograms and the description has been rewritten.	Page 11, lines 1-25 & Fig. 4, caption
2	Discussion about mitochondrial DNA and inflammasomes has been appended.	Page 16, line 54 - page 17, line 9
3	Supplementary data for characterization of nanoparticles have been appended.	Page 8, lines 26-38 & Fig. S1
4	The p values for ANOVA analysis have been included.	Fig. 1 & caption
5	Fig. 7 has been removed.	
6	TEM images of a control cell and a cell treated with 100 nm particles have been appended.	Fig. 5

35

그리고

짧을수록 좋다

길수록 좋다

더 많은 시간

더 많은 생각

더 자세히

더 겸손하고 감사하게

36

감사합니다

KAMJE Workshop

2013. 09. 07